Skip to Content

Thalidomide Disease Interactions

There are 5 disease interactions with thalidomide:

Moderate

Thalidomide (applies to thalidomide) seizures

Moderate Potential Hazard, Moderate plausibility.

Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice. Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence. During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.

Moderate

Thalidomide (applies to thalidomide) HIV infection

Moderate Potential Hazard, Moderate plausibility.

In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels. The clinical significance of this finding is unknown. Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART. Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient's antiretroviral regimen and clinical status).

References

  1. "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.
Moderate

Thalidomide (applies to thalidomide) hypotension

Moderate Potential Hazard, Moderate plausibility.

The use of thalidomide has been associated with dizziness and orthostatic hypotension. Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension. Rising slowly from a recumbent position is recommended.

References

  1. "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.
Moderate

Thalidomide (applies to thalidomide) neutropenia

Moderate Potential Hazard, Moderate plausibility.

The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia. Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia. Treatment should not be initiated if absolute neutrophil count is below 750/mm3. Monitoring white blood cell count and differential routinely is recommended during treatment.

References

  1. "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.
Moderate

Thalidomide (applies to thalidomide) peripheral neuropathy

Moderate Potential Hazard, High plausibility.

The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible. Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline. Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet. If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.

References

  1. "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.

Thalidomide drug interactions

There are 715 drug interactions with thalidomide

Thalidomide alcohol/food interactions

There is 1 alcohol/food interaction with thalidomide

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.